Emcure Pharmaceuticals Limited — Investor Meet, 13-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Emcure Pharmaceuticals started FY26 strong: Revenue up 15.7% to INR 2,101 Cr, EBITDA 20.1% to INR 404 Cr, and PAT surged 41% to a record INR 215 Cr. Domestic business grew 9.4%, International 22% (Emerging Markets +42%, Canada +16.4%, Europe +12.8%). Margins improved to 19.2%.

The company targets 2% above industry growth and 300-400 bps EBITDA margin expansion over five years. Key moves include integrating Sanofi's diabetes portfolio, launching new Derma/wellness initiatives, and progressing complex products like Liposomal Amphotericin B and Semaglutide. Gross debt is around INR 700 Cr, with plans for reduction post recent acquisitions. Management expresses confidence in future growth through innovation and strategic partnerships.